Evidence Table 161. KQ4—Cmax

| **Author Year**  **Study Design** | **Definition of outcome** | **CHD Risk Category** | **CVD drug (dose mg/d)** | **Supplement/ Control** | **N** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change / % change from baseline /**  **SD /**  **P Value** | **Between group differences in Means / medians**  **SD /**  **P Value** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Kim 201035  Cross-over | ng/mL – measured after single dose of ticlopidine and single dose Ginkgo biloba | Low and/or Moderate | Ticlopidine (250; single dose) | Ginkgo biloba (0.08; single dose) | 24 | Mean: 1071.6  SD: 484.1 | GMR: 963.7 | GMRdiff: 1.03  Lower: 0.92  Upper: 1.16 | Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 24 | Mean: 1027.0  SD: 437.2 | GMR: 932.6 |
| Hadja 201028  Cross-over | µg/L | Low (healthy men) | Simvastatin  (20) | Garlic (600 mg twice daily) | 10 | Mean: 5.25  SD: 6.32 | - | - | - | Medium |
| No treatment | 10 | Mean: 3.85  SD: 1.99 | - | - | - | Medium |
| Hadja 201028  Cross-over | µg/L | Low (healthy men) | Pravastatin  (20) | Garlic (600 mg twice daily) | 10 | Mean: 14.2  SD: 6.7 | - | - | - | Medium |
| No treatment | 10 | Mean: 18.8  SD: 12.2 | - | - | - | Medium |
| Tankanow 200365  Cross-over | ng/mL: Measured after 10 days digoxin or 21 days digoxin + hawthorn | Low (healthy) | Digoxin (0.25) | Hawthorn (0.9) | 8 | Mean: 1.80  SD: 0.20 | - | - | - | Medium |
| No treatment | 8 | Mean: 2.10  SD: 0.60 | - |
| Mauro 200343  Cross-over | ng/mL; Measured after single-dose administration of digoxin following 7 days pre-treatment with Ginkgo biloba or no pre-treatment | Low (healthy) | Digoxin (0.5; single dose) | *Ginkgo biloba* (0.24) | 8 | Mean: 1.4  SD: 0.5 | - | - | - | Medium |
| No treatment | 8 | Mean: 1.6  SD: 0.3 | - |

| Evidence Table 161. KQ4—Cmax (continued) | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author Year**  **Study Design** | **Definition of outcome** | **CHD Risk Category** | **CVD drug (dose mg/d)** | **Supplement/ Control** | **N** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| Jiang 200433  Cross-over | R-Warfarin:  µg/mL; measured after single dose warfarin following 1 week pretreatment with ginseng or no pretreatment. Subjects followed for one more week post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | Ginseng (3) | 12 | Mean: 1.89  SD: 0.29  Lower: 1.70  Upper: 2.00 | - | GMRdiff: 0.98  Lower: 0.88  Upper: 1.09 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 1.92  SD: 0.32  Lower: 1.70  Upper: 2.10 | - |
| S-Warfarin:  µg/mL; measured after single-dose warfarin following 1 wk pretreatment with ginseng or no pretreatment. Subjects followed for 1 wk post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | Ginseng (3) | 12 | Mean: 1.93  SD: 0.31  Lower: 1.70  Upper: 2.10 | *-* | GMRdiff:1.01  Lower: 0.90  Upper: 1.12 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 1.89  SD: 0.26  Lower: 1.70  Upper: 2.00 | *-* |
| Jiang 200532  Cross-over | R-Warfarin:  µg/mL; measured after single dose warfarin following 1 week pretreatment with Ginger, Ginkgo biloba or no pretreatment. Subjects followed for one more week post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | Ginger (3.6) | 12 | Mean:1.70  Lower: 1.50  Upper: 1.90 | - | Ginger  GMRdiff: 1.02  Lower: 0.95  Upper: 1.07  Ginkgo biloba  GMRdiff: 1.03  Lower: 0.97  Upper:1.10 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
|  |  |  | Ginkgo biloba(12) | 12 | Mean: 1.80  Lower: 1.50  Upper: 2.00 | - |  |  |
| No treatment | 12 | Mean: 1.70  Lower: 1.40  Upper: 2.00 | - |  |
| S-Warfarin:  µg/mL; measured after single-dose warfarin following 1 wk pretreatment with Ginger, Ginkgo biloba or no pretreatment. Subjects followed for 1 wk post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | Ginger (3.6) | 12 | Mean: 1.70  Lower: 1.50  Upper: 2.00 | - | Ginger  GMRdiff:1.01  Lower: 0.94  Upper:1.07  Ginkgo biloba  GMRdiff:1.04  Lower: 0.97  Upper:1.09 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| *Ginkgo biloba* (12) | 12 | Mean:0.12  Lower: 0.11  Upper: 0.13 | - |
| No treatment | 12 | Mean:0.12  Lower: 0.11  Upper: 0.14 |  |
| Gosai 200826  Cross-over | ng/mL; 2 weeks treatment | Low (healthy) | Rovustatin (40) | Omega-3 fatty acids (EPA, DHA or both) (4) | 42 | Mean: 25.51  SD: 11.75 | - | GMRdiff: 1.01  Lower: 0.94  Upper: 1.09 | % coefficient of variation:  Omega-3: 46.08  Control: 34.85  Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 41 | Mean: 24.3  SD: 8.47 | - |
| Di Spirito 200819  Cross-over | Atorvastatin; Day 14 steady state (ng/mL); 2 weeks treatment | Low (healthy) | Atorvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 49 | Mean: 52.1  SD: 62 | - | GMRdiff: 1.03  Lower: 0.93  Upper: 1.14 | Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 49 | Mean: 50.9  SD: 51 | - |
| 2-hydroxytorvastatin; Day 14 steady state; (ng/mL); 2 weeks treatment | Low (healthy) | Atorvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 49 | Mean: 45  SD: 59.3 | - | GMRdiff: 0.95  Lower: 0.85  Upper: 1.06 | Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 49 | Mean: 47.6  SD: 50 | - |
| Mohammed Abdul 200849  Cross-over | R-Warfarin:  µg/mL; measured after single dose warfarin following 2 wks pretreatment with garlic or no pretreatment. Subjects followed for one more week post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | Garlic (4; 7.42 mg allicin) | 12 | Mean: 1.9  Lower: 1.5  Upper: 2.2 | - | GMRdiff: 1.02  Lower: 0.80  Upper:1.40 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 1.8  Lower: 1.7  Upper: 2.0 | - |
| S-Warfarin:  µg/mL; measured after single dose warfarin following 2 wks pretreatment with garlic or no pretreatment. Subjects followed for one more week post warfarin dose | Low (healthy) | Warfarin (25; single dose) | Garlic (4; 7.42 mg allicin) | 12 | Mean: 1.9  Lower: 1.5  Upper: 2.2 | - | GMRdiff: 1.06  Lower: 0.70  Upper:1.47 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 1.8  Lower: 1.7  Upper: 1.9 | - |
| McKenney 200645  Cross-over | Simvastatin; Cmax over final dosing interval (ng/mL); 2 wk treatment. | Low and/or Moderate | Simvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 24 | Mean: 15.4  SD: 7.6 | - | - | - | Medium |
| No treatment | 23 | Mean: 13.5  SD: 6.1 | - |
| Beta-hydroxy simvastatin; Cmax over final dosing interval (ng/mL); 2 wk treatment. | Low and/or Moderate | Simvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 24 | Mean: 6.1  SD: 3.6 | - | - | - | Medium |
| No treatment | 23 | Mean: 6.1  SD: 3.2 | - |
| Abdul 20101  Cross-over | R-Warfarin:  µg/mL (1 hour); measured after single dose warfarin following 2 wks pretreatment with Echinacea or no pretreatment. Subjects followed for one more week post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | *Echinacea* (5.1; 23 mg total alkamides) | 12 | Mean:1.20  Lower: 1.10  Upper: 1.40 | - | GMRdiff: 0.98  Lower: 0.88  Upper: 1.10 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 1.30  Lower: 1.10  Upper: 1.50 | - |
| S-Warfarin:  µg/mL (1 hour); measured after single dose warfarin following 2 wks pretreatment with Echinacea or no pretreatment. Subjects followed for one more week post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | *Echinacea* (5.1; 23 mg total alkamides) | 12 | Mean: 1.30  Lower: 1.10  Upper: 1.43 | - | GMRdiff: 0.97  Lower: 0.86  Upper: 1.10 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 1.30  Lower: 1.10  Upper: 1.60 | - |